What Are the Side Effects of Ritonavir?

Ritonavir’s most common side effects are gastrointestinal problems like diarrhea, nausea, and vomiting, followed by metabolic changes such as elevated blood lipids and blood sugar disturbances. How much trouble the drug causes depends heavily on how it is being used: at full therapeutic doses it earned a reputation as one of the least tolerable HIV protease inhibitors, but at the low “booster” doses used in most modern regimens, its direct side-effect contribution shrinks considerably. Because ritonavir powerfully inhibits liver enzymes that break down other medications, many of the side effects people experience while taking it are actually driven by drug-drug interactions rather than by ritonavir itself.

Why Ritonavir Is Rarely the Main Drug Anymore

Ritonavir was originally developed as a full-strength HIV protease inhibitor, prescribed at 600 mg twice daily. At that dose, it suppressed HIV effectively but caused enough nausea, diarrhea, and metabolic disruption that many patients could not stay on it. A study comparing protease inhibitors found that starting full-dose ritonavir carried a three- to sixfold higher risk of treatment-limiting side effects compared with other protease inhibitors available at the time.¹

Today, ritonavir is almost always used at a much lower dose, typically 100 to 200 mg, as a “pharmacokinetic booster.” It blocks an enzyme in the liver called CYP3A4, which is responsible for breaking down many other drugs. By slowing that enzyme, a small dose of ritonavir dramatically raises blood levels of whichever protease inhibitor it is paired with, allowing that partner drug to work longer and at higher concentrations without needing to be taken as often.² At booster doses, ritonavir contributes much less to the overall side-effect picture of a regimen, though it does not become invisible.

This same boosting mechanism is the reason ritonavir shows up in Paxlovid, the COVID-19 antiviral. In that combination, ritonavir is paired with nirmatrelvir and exists solely to keep nirmatrelvir in the bloodstream longer. If you were prescribed Paxlovid and looked up ritonavir side effects, the context matters: the short five-day course produces a different side-effect experience than long-term use in HIV therapy.

Gastrointestinal Effects

Gut problems are the side effect most people notice first. Diarrhea tops the list, and ritonavir is particularly associated with it, even when used at booster doses. Among regimens that combine ritonavir with another protease inhibitor, the combinations most strongly linked with moderate to severe diarrhea are lopinavir-ritonavir and fosamprenavir-ritonavir, while atazanavir-ritonavir, darunavir-ritonavir, and saquinavir-ritonavir tend to cause less.³ Nausea and vomiting are also common, especially in the first weeks of treatment, and tend to lessen over time as the body adjusts.

One practical way to reduce stomach upset is to take ritonavir with food. A systematic review of how antiretroviral drugs interact with meals found that ritonavir should be taken with or immediately after a meal.⁴ Eating first can both improve absorption and blunt the nausea that sometimes accompanies the drug on an empty stomach.

A note on taste: ritonavir itself tastes bitter, and people taking it in liquid form often notice this. However, the persistent metallic or bitter taste that Paxlovid users complain about, sometimes called “Paxlovid mouth,” appears to be caused by nirmatrelvir rather than ritonavir. Research suggests nirmatrelvir activates bitter taste receptors in a way that ritonavir alone does not.⁵ So if you have taken Paxlovid and experienced a lingering awful taste, ritonavir probably was not the culprit.

Metabolic Side Effects

Beyond the gut, ritonavir’s most clinically significant effects are metabolic. These show up in blood work rather than as symptoms you can feel, which is why routine lab monitoring matters for anyone taking ritonavir-containing regimens long-term.

Elevated blood lipids are the metabolic issue most closely tied to ritonavir specifically. Among all protease inhibitors, ritonavir has the strongest association with high triglycerides.⁶ Animal studies have shown that the drug ramps up fatty acid and cholesterol production in the liver by causing a buildup of proteins that regulate lipid-making genes.⁷ In practical terms, this means your doctor will check cholesterol and triglyceride levels regularly and may add a statin or other lipid-lowering drug if numbers climb too high.

Blood sugar is the other metabolic concern. Ritonavir can impair how your body handles glucose by directly interfering with a transporter protein called GLUT4, which is responsible for moving sugar from the bloodstream into muscle and fat cells.⁸ For most people this shows up as mildly elevated fasting glucose, but for those who are already prediabetic or diabetic, it can push blood sugar control in the wrong direction.

Fat Redistribution and Body Shape Changes

One of the more distressing side effects linked to protease inhibitor therapy overall is lipodystrophy, a collection of body-shape changes that can include fat loss in the face, arms, and legs (lipoatrophy) and fat gain around the abdomen, back of the neck, or breasts (lipoaccumulation). For years, protease inhibitors like ritonavir bore the blame for this. More recent research has complicated that picture.

A trial comparing lopinavir-ritonavir used alone versus lopinavir-ritonavir combined with two nucleoside drugs found that patients on the triple combination lost significantly more limb fat over 48 weeks. Fat loss meeting a clinical threshold happened in about 27% of the triple-therapy group but only about 5% of those on lopinavir-ritonavir alone.⁹ The treatment regimen, not the protease inhibitor itself, was the only significant predictor of fat loss. This suggests that older nucleoside drugs, particularly thymidine analogs like zidovudine, were the bigger drivers of lipoatrophy, and that ritonavir-boosted protease inhibitors on their own may contribute less to this problem than was originally feared.

That said, fat redistribution has not disappeared entirely with modern regimens. Some degree of trunk fat gain appears to occur across several drug classes and may be related to HIV infection itself, immune recovery, or lifestyle factors. Lipodystrophy is still listed as a class effect of protease inhibitors that warrants monitoring.

Liver Effects

Because ritonavir is metabolized in the liver and because it changes how the liver processes other drugs, liver injury is a recognized risk. Elevations in liver enzymes (AST and ALT on a blood panel) can occur, and in a cohort study of patients on lopinavir-ritonavir, liver enzyme elevations were the third most common reason for stopping the drug, after gastrointestinal symptoms and high blood lipids.¹⁰

The risk of liver toxicity goes up when ritonavir-containing regimens are combined with other drugs that also rely on the CYP3A4 enzyme for breakdown. This became a visible problem during the early COVID-19 pandemic, when lopinavir-ritonavir was tried alongside hydroxychloroquine and chloroquine. Analysis of adverse-event reports found that physicians needed to be alert to heightened liver injury risk in those combinations.¹¹ People with pre-existing liver disease, including hepatitis B or C coinfection, face higher baseline risk and need closer monitoring.

Heart Rhythm Concerns

Ritonavir has the potential to affect the electrical timing of the heart. A systematic review examining several protease inhibitors, including ritonavir, found evidence that they could cause PR prolongation, QRS widening, and QT prolongation, all of which are changes in the heart’s electrical cycle that, in extreme cases, can lead to dangerous arrhythmias.¹² The review noted, however, that the evidence base was limited to small studies.

A cohort study of patients treated with lopinavir-ritonavir for COVID-19 found that the average corrected QT interval increased from about 416 milliseconds before treatment to about 438 milliseconds afterward. The clinically meaningful QT prolongation, though, appeared only in patients who already had cardiovascular conditions, angina, or low magnesium levels.¹³ In other words, people with healthy hearts at baseline tolerated the drug without clinically significant rhythm changes. This is consistent with the general clinical experience: cardiac effects are a real consideration, especially when ritonavir is combined with other drugs that also lengthen the QT interval, but they rarely cause problems in people without underlying heart disease.

Kidney Effects

Ritonavir is not generally considered toxic to the kidneys, and serious renal problems are rare enough that individual case reports have been published as novel findings. One such report documented acute kidney injury confirmed by biopsy showing extensive tubular damage, described as the first documented kidney biopsy in ritonavir-associated kidney injury.¹⁴ The rarity of published kidney cases suggests this is a side effect to be aware of but not one that drives routine clinical concern for most patients.

Drug Interactions as a Side-Effect Multiplier

This is arguably the most important section for anyone taking ritonavir, because the drug’s capacity to cause harm extends well beyond its own direct effects. By powerfully blocking CYP3A4, ritonavir can cause blood levels of dozens of other medications to spike far above their intended range, turning an otherwise safe dose of another drug into a dangerous one.

The consequences depend on what the co-administered drug is. For cancer patients taking certain targeted therapies, the interaction can increase the risk of severe toxicities like lung inflammation, liver damage, and QT prolongation, because those drugs already have a narrow margin between an effective dose and a toxic one.¹⁵ Similar principles apply to immunosuppressants used after organ transplant, certain heart medications, sedatives, and some psychiatric drugs. The list of potential interactions is long enough that checking for them before starting ritonavir is standard medical practice.

For people prescribed Paxlovid for a short course, this interaction issue can be especially tricky. You might not think of a five-day antiviral as carrying the same risks as a long-term HIV regimen, but the CYP3A4 inhibition kicks in quickly. If you take medications for blood pressure, cholesterol, chronic pain, anxiety, or organ transplant rejection, your prescriber needs to know before you start, because some drugs must be paused or dose-adjusted during and even for a few days after the Paxlovid course.

Skin Reactions

Skin problems are less commonly discussed with ritonavir than gastrointestinal or metabolic effects, but they do occur. People starting antiretroviral therapy in general can develop drug rashes, hives, hair thinning, and hyperpigmentation. In rare cases, more serious hypersensitivity reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported with antiretroviral drugs as a class.¹⁶ These severe reactions are extremely rare with ritonavir specifically, but any new unexplained rash that appears shortly after starting the drug warrants prompt medical attention.

Who Is More Likely to Have Problems

Side effects from ritonavir are not evenly distributed across all patients. Body weight is one clear predictor: lower body weight at the time of starting a protease inhibitor regimen independently increases the risk of treatment-limiting side effects, with the risk climbing roughly 12% for every 5 kilograms lighter a person is.¹⁷ This makes intuitive sense: a lower body weight means higher drug concentrations per kilogram, amplifying both effects and side effects.

Genetics also play a role, though the science is still evolving. Variations in genes that code for drug-metabolizing enzymes and drug-transporter proteins can influence how much ritonavir accumulates inside cells.¹⁸ For instance, people carrying certain variants of the OATP1B1 transporter gene or the PXR gene have been found to have higher ritonavir concentrations inside cells, which could translate to a greater burden of side effects at the same oral dose.¹⁹ Routine genetic testing before prescribing ritonavir is not standard practice, but pharmacogenomic testing is gradually becoming more accessible and may eventually inform dose selection.

Pre-existing conditions also matter. As noted in the heart rhythm section, people with cardiovascular disease or electrolyte imbalances face higher cardiac risk. Those with liver disease face higher hepatotoxicity risk. And people who are already prediabetic or who have high cholesterol at baseline are more likely to see those numbers worsen.

How Often People Stop Because of Side Effects

Discontinuation rates offer a reality check on how tolerable a drug actually is in everyday use. In a cohort of 416 heavily treatment-experienced HIV patients on lopinavir-ritonavir, about 19% eventually stopped the drug because of side effects. The probability of stopping for toxicity was roughly 5% at one year and about 16% at two years.²⁰ An encouraging detail: the risk of stopping decreased by about 17% for each additional month of exposure, meaning that people who tolerated the drug in the early months were increasingly likely to continue tolerating it over time.

Gastrointestinal symptoms were the leading cause of discontinuation, followed by lipid abnormalities and liver enzyme elevations. This pattern reflects the timeline of side effects: gut problems tend to hit early and drive the most acute discomfort, while metabolic effects emerge gradually on lab work and lead to later switches.

Cobicistat as an Alternative Booster

Because many of ritonavir’s side effects stem from its identity as a protease inhibitor, not just an enzyme blocker, another booster drug called cobicistat was developed. Cobicistat inhibits CYP3A4 in a similar way to ritonavir but is not itself an antiretroviral, so it does not carry the protease inhibitor class effects.

In practice, the difference between the two boosters is modest. A 144-week randomized trial comparing atazanavir boosted with cobicistat versus atazanavir boosted with ritonavir found similar rates of viral suppression and overall adverse events, with about 11% in each group discontinuing due to side effects.²¹ Cobicistat did cause a slightly larger drop in estimated kidney filtration rate, which is a known effect of how cobicistat interacts with creatinine measurements rather than a sign of true kidney damage.

A Romanian study comparing darunavir paired with ritonavir versus darunavir paired with cobicistat found that the cobicistat group was better tolerated and had a more favorable metabolic profile, with statistically significant differences in side effects and metabolic markers over time.²² Part of the metabolic advantage may come from the dosing schedule: in that study, the ritonavir group took their drugs twice daily while the cobicistat group took theirs once daily, and once-daily dosing itself can affect peak drug levels. Still, for people who struggle specifically with ritonavir’s metabolic effects, switching to a cobicistat-boosted regimen is a reasonable conversation to have with a provider.

Ritonavir in Pregnancy

Pregnant women living with HIV often need protease inhibitor therapy, and lopinavir-ritonavir has been one of the most studied combinations in this population. A systematic review found no unique safety or efficacy concerns with standard-dose lopinavir-ritonavir during pregnancy. Preterm delivery rates ranged from about 8% to 25%, and low birth weight occurred in 11% to 20% of cases, rates broadly consistent with what is seen in HIV-positive pregnant women on other regimens.²³

Large surveillance datasets, including the French Perinatal Cohort and the Antiretroviral Pregnancy Registry, have found no increase in birth defect rates associated with lopinavir-ritonavir exposure, including first-trimester exposure. The overall congenital abnormality rate in one large UK and Ireland dataset was about 2.9%, comparable to the general population without HIV.²⁴

More recently, ritonavir gained relevance in pregnancy through Paxlovid. A case series evaluating nirmatrelvir-ritonavir in pregnant patients with acute COVID-19 found the combination appeared safe and effective, and the authors argued it could serve as a first-line outpatient treatment given that other COVID therapies are either intravenous or contraindicated in pregnancy.²⁵ The data is still limited, but the early signals are reassuring.